弘宇股份(002890) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥70,020,846.46, a decrease of 2.35% compared to the same period last year[3]. - The net profit attributable to shareholders for the same period was ¥4,555,696.43, down 7.81% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥3,381,905.63, reflecting a decline of 9.30% compared to the previous year[3]. - Total operating revenue for Q3 2024 was CNY 255,937,794.46, a decrease of 10.0% compared to CNY 284,272,558.68 in the same period last year[12]. - Total operating costs for Q3 2024 were CNY 244,507,497.70, down 9.2% from CNY 269,440,622.85 year-on-year[12]. - The net profit for Q3 2024 was CNY 13,779,672.27, a decrease of 11.7% compared to CNY 15,603,049.87 in Q3 2023[13]. - Operating profit for Q3 2024 was CNY 14,943,768.61, down from CNY 16,808,341.03 in the same period last year[13]. - The total profit for Q3 2024 was CNY 14,777,003.79, a decline of 13.0% from CNY 16,993,639.60 in Q3 2023[13]. - Basic earnings per share for Q3 2024 were CNY 0.0811, compared to CNY 0.0919 in Q3 2023, reflecting a decrease of 11.8%[13]. Cash Flow and Assets - The cash flow from operating activities showed a significant increase, reaching ¥14,338,103.52, up 103.78% year-on-year[3]. - Cash flow from operating activities generated a net amount of CNY 14,338,103.52, an increase of 103.7% compared to CNY 7,036,071.63 in Q3 2023[14]. - The company reported cash and cash equivalents at the end of Q3 2024 amounting to CNY 44,457,697.36, down from CNY 58,040,379.52 at the end of Q3 2023[15]. - Cash and cash equivalents decreased to ¥44,457,697.36 from ¥64,745,830.37, representing a decline of about 31.3%[9]. - The total current assets at the end of Q3 2024 amounted to ¥535,972,236.79, slightly down from ¥535,993,433.64 at the beginning of the period, indicating a decrease of approximately 0.004%[9]. - The company reported a significant increase in trading financial assets, which rose to ¥203,655,820.62 from ¥185,196,921.69, a growth of about 10.0%[9]. - The company experienced a 72.28% increase in financial expenses compared to the previous year, mainly due to reduced interest income and exchange losses[6]. - The net cash flow from investment activities decreased by 349.92% year-on-year, primarily due to higher investment in financial products compared to recoveries[6]. Shareholder and Equity Information - The company's equity attributable to shareholders increased to ¥591,260,804.52, up 0.16% from the previous year[3]. - The number of ordinary shareholders at the end of the reporting period was 6,693[7]. - Net profit attributable to the parent company was not explicitly stated, but the total equity attributable to shareholders reached CNY 591,260,804.52, slightly up from CNY 590,314,620.14[11]. - The company maintained a stable retained earnings balance of CNY 272,455,006.00, slightly up from CNY 271,733,464.00, indicating consistent profitability[12]. Liabilities and Expenses - Current liabilities totaled CNY 134,296,737.94, down from CNY 136,676,119.58, indicating improved liquidity management[12]. - The total liabilities decreased to CNY 145,565,400.22 from CNY 147,096,121.28, showing a reduction in financial obligations[12]. - The company reported a decrease in employee compensation payable to CNY 11,199,735.48 from CNY 13,590,361.13, indicating potential cost-cutting measures[12]. - Research and development expenses for Q3 2024 were CNY 9,744,437.29, slightly down from CNY 9,769,181.65 in the previous year[12]. Other Notable Information - The company reported a significant increase in other income, which rose by 893.29% year-on-year, primarily due to increased VAT deductions[6]. - The company has not disclosed any new product developments or technological advancements in this report[9]. - There are no updates on market expansion or mergers and acquisitions in the current quarter[9]. - The report does not provide specific future guidance or performance outlook for the upcoming quarters[9]. - The total liabilities at the end of Q3 2024 were not explicitly stated but are essential for assessing the company's financial health[9].